On January 22, 2026, Merck & Co. Inc. announced a landmark multi-year agreement with Guardant Health to leverage the company’s Guardant Infinity Smart liquid biopsy platform for the development and commercialization of Merck’s oncology pipeline. Under the deal, Guardant Health will apply its high-sensitivity circulating tumor DNA assay to identify emerging resistance mutations and guide patient selection across Merck’s late-stage clinical trials in lung, colorectal and melanoma indications. The collaboration grants Merck access to real-time genomic monitoring in more than 20,000 patients annually, accelerating go/no-go decisions and adaptive trial designs. Financial terms include a USD 150 million upfront payment to Guardant Health and tiered royalties on future companion diagnostic tests. The partnership aims to reduce diagnostic turnaround times from tissue-based profiling’s standard 14 days to under 7 days, enabling earlier intervention with Merck’s checkpoint inhibitors and targeted agents. Investors are watching for pilot data expected in mid-2026 from a Phase 2 non–small cell lung cancer study, which could pave the way for expanded regulatory submissions and companion diagnostic approvals in Europe and Asia.

This collaboration strengthens Merck’s competitive positioning against rival immunotherapy developers by integrating cutting-edge liquid biopsy tools into its clinical development strategy. Merck currently allocates over USD 5 billion annually to oncology research and development, with the guardant partnership expected to improve trial enrollment efficiency by up to 25%, according to internal estimates. Rapid, non-invasive genomic profiling may also expand Merck’s ability to secure breakthrough therapy designations, potentially shortening time-to-market for next-generation PD-1 and LAG-3 inhibitors. Analysts at Jefferies project that faster biomarker-driven patient stratification could boost peak sales of Merck’s mid-stage programs by as much as USD 500 million per indication. Additionally, the collaboration underlines Merck’s broader strategy to build a diagnostics ecosystem, complementing its existing investments in internal molecular pathology and third-party CDMOs.